New treatment tested to protect kids with weak immune systems
Disease control
Ongoing
This study is testing a specific brand of intravenous immunoglobulin (IVIg) treatment in children aged 2 to 16 who have primary immunodeficiency disease (PID). The main goal is to see how well this treatment prevents serious bacterial infections, like pneumonia or sepsis. Researc…
Phase: PHASE3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC